Skip to content

ESC/EAS 2019: dyslipidaemias

International ESC/EAS Current

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Mach F, et al. Eur Heart J. 2020;41:111–188
DOI 10.1093/eurheartj/ehz455 · Summary checked against the source: 2026-11

Read or download the original

Still the main ESC/EAS lipid guideline; the 2025 focused update adds to it (SCORE2, bempedoic acid, ACS, Lp(a), HIV, cancer). Pages are from Eur Heart J 2020;41:111–188.

At a glance

  1. "Lower is better": LDL-C goals fall with risk: very high <1.4 mmol/L (55 mg/dL) and ≥50% reduction; high <1.8 (70); moderate <2.6 (100); low <3.0 (116). [Table 7 · p. 133]
  2. Treatment ladder: high-intensity statin to the maximum tolerated dose → add ezetimibe → add a PCSK9 inhibitor. [I, A; I, B; I, A · p. 145]
  3. Measure Lp(a) at least once in every adult: >180 mg/dL (>430 nmol/L) carries a risk like heterozygous FH. [IIa, C · p. 119]
  4. Imaging can reclassify risk: significant plaque on angiography or CT, or carotid plaque, = very high risk; CAC >100 = high or very high. [Table 4 · p. 125]
  5. TG 135–499 mg/dL on a statin in high-risk patients: icosapent ethyl 2 g twice daily. [IIa, B · p. 119]

Risk categories and goals

Risk Who LDL-C goal
Very high Documented ASCVD (clinical or unequivocal on imaging); diabetes with target-organ damage, ≥3 major risk factors, or type 1 for >20 years; eGFR <30; SCORE ≥10%; FH with ASCVD or another major risk factor <1.4 mmol/L (<55 mg/dL) and ≥50% reduction
High Markedly raised single risk factor (TC >8 mmol/L, LDL-C >4.9 mmol/L [190 mg/dL], BP ≥180/110); FH without other risk factors; eGFR 30–59; diabetes ≥10 years without organ damage; SCORE 5–<10% <1.8 mmol/L (<70 mg/dL) and ≥50% reduction
Moderate Young diabetes (type 1 <35, type 2 <50 years, <10 years' duration, no risk factors); SCORE 1–<5% <2.6 mmol/L (<100 mg/dL)
Low SCORE <1% <3.0 mmol/L (<116 mg/dL)

Secondary goals: non-HDL-C <2.2, 2.6, 3.4 mmol/L (85, 100, 130 mg/dL) and apoB <65, 80, 100 mg/dL for very-high, high and moderate risk. No TG goal, but <1.7 mmol/L (150 mg/dL) means lower risk. Adapted from ESC/EAS 2019 Table 4, Table 7 and Figure 4B [p. 125, 133, 147]

Treatment algorithm

flowchart TD
    A["Total CV risk assessment (Table 4)<br/>Baseline LDL-C"] --> M["Low or moderate risk, selected patients:<br/>risk modifiers, imaging, reclassification"]
    A --> I{"Drug therapy indicated?<br/>(Table 5)"}
    M --> I
    I -->|No| L["Lifestyle advice"]
    I -->|Yes| G["Define treatment goal (Table 7)"]
    G --> S["High-potency statin at the highest<br/>recommended or tolerated dose"]
    S --> Q1{"LDL-C goal reached?"}
    Q1 -->|Yes| F1["Follow-up yearly<br/>(or more often)"]
    Q1 -->|No| E["Add ezetimibe"]
    E --> Q2{"LDL-C goal reached?"}
    Q2 -->|Yes| F2["Follow-up yearly<br/>(or more often)"]
    Q2 -->|No| P["Add PCSK9 inhibitor:<br/>secondary prevention (very high risk);<br/>FH with another major risk factor"]
    Q2 -->|No| P2["Consider PCSK9 inhibitor:<br/>primary prevention, very high risk without FH"]
Adapted from ESC/EAS 2019 Figure 4A [p. 147]

Recommendation Class, level
High-intensity statin up to the highest tolerated dose to reach the goal I, A
Not at goal on maximal statin: add ezetimibe I, B
Secondary prevention, very high risk, not at goal on statin + ezetimibe: add a PCSK9 inhibitor I, A
FH at very high risk (ASCVD or another major risk factor) not at goal: PCSK9 inhibitor I, C
Primary prevention, very high risk without FH, not at goal: PCSK9 inhibitor may be considered IIb, C
Statin not tolerated at any dose: ezetimibe IIa, C

Adapted from ESC/EAS 2019 recommendations for pharmacological LDL-C lowering [p. 145]

Other key recommendations

  • Lp(a) once in a lifetime. [IIa, C · p. 119]
  • Hypertriglyceridaemia: statins first; in high-risk patients with TG 1.5–5.6 mmol/L (135–499 mg/dL) despite a statin, icosapent ethyl 2 g twice daily. [IIa, B · p. 119]
  • FH at very high risk, primary prevention: ≥50% reduction and LDL-C <1.4 mmol/L. [IIa · p. 119]
  • Older people: statins for primary prevention by risk up to 75; may be considered above 75 if at high risk. [I; IIb · p. 119]
  • Type 2 diabetes: very high risk <1.4 mmol/L, high risk <1.8 mmol/L, both with ≥50% reduction; statins for type 1 diabetes at high or very high risk. [I · p. 119]
  • Drug treatment of TG may be considered only in high-risk patients with TG >2.3 mmol/L (200 mg/dL) despite lifestyle. [p. 145]
  • Familial combined hyperlipidaemia: suspect with apoB >120 mg/dL + TG >1.5 mmol/L and a family history of premature CVD. [p. 148]

Clinical pearls

  • Very high risk: <55 mg/dL (1.4 mmol/L) and ≥50% fall. Recurrent event within 2 years on maximal therapy: <40 mg/dL may be considered.
  • Statin → ezetimibe → PCSK9 inhibitor.
  • LDL-C ≥4.9 mmol/L (190 mg/dL) = high risk on its own; think FH (Dutch Lipid Clinic Network score).
  • Lp(a) is genetically determined: measure once.

Classes and levels of evidence

How ESC/EAS 2019 grades its recommendations. Adapted from ESC/EAS 2019 Tables 1 and 2 [p. 117]. Hover over any class or level cited on this page to see what it means.

Class Meaning Wording used
Class I Evidence and/or general agreement that a treatment or procedure is beneficial, useful and effective is recommended or is indicated
Class IIa Weight of evidence or opinion is in favour of usefulness or efficacy should be considered
Class IIb Usefulness or efficacy is less well established by evidence or opinion may be considered
Class III Evidence or general agreement that the treatment or procedure isn't useful or effective, and in some cases may be harmful is not recommended
Level Meaning
Level A Data from multiple randomised clinical trials or meta-analyses
Level B Data from a single randomised clinical trial or large non-randomised studies
Level C Consensus of expert opinion and/or small studies, retrospective studies, registries

Class II covers conflicting evidence or a divergence of opinion about usefulness or efficacy. It's split into IIa and IIb.